Eftilagimod alfa
As of the edition of 20 October 2026, Eftilagimod alfa is a drug: in active development; acts on LAG3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Unknown
- Registered trials
- 15, 3 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| LAG3 | Lymphocyte activation gene 3 protein | P18627 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 5 | 1 | 1 |
| Phase 2 | 6 | 3 | 2 | 1 |
| Phase 3 | 2 | 0 | 1 | 1 |
| All trials | 15 |